New Antiretroviral Drugs in the Pandemic


  • Thana Khawcharoenporn Division of Infectious Diseases, Faculty of Medicine, Thammasat University, Pathum Thani, Thailand



New, Antiretroviral drugs, Pandemic, HIV, Long-acting


The pandemic of coronavirus disease-19 (COVID-19) has impacted the care of people living with human immunodeficiency virus (HIV) and HIV prevention in several ways. Locking down and limiting transportation to slow down COVID-19 transmission can cause difficulty accessing and non-compliance to daily-dosing antiretroviral drugs (ARVs). The new formu-lations of ARVs, including long-acting ones administered as injections and implants are being approved and developed for HIV treatment and prevention. Intramuscular cabotegravir and rilpivirine co-formulation is approved by the US Food and Drug Administration for HIV treatment in virologically suppressed adults on a stable regimen, while intramuscular cabotegravir is approved for HIV pre-exposure prophylaxis. Other long-acting drugs, such as lenacapavir and islatravir have currently been developed and studied for HIV treatment and/or prevention. This present article concisely reviews the current knowledge on these new ARVs and their implications, which may serve as novel regimens for use during the current and future pandemics.


Download data is not yet available.




How to Cite

Khawcharoenporn, T. 2022. New Antiretroviral Drugs in the Pandemic. Asian Medical Journal and Alternative Medicine. 22, - (Aug. 2022), S50-S61. DOI: